Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors

Mayur Garg; Simon G. Royce; John S. Lubel

doi:10.1111/apt.15814

Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors

Mayur Garg, Simon G. Royce, John S. Lubel

Research output: Contribution to journal › Letter › Other › peer-review

1 Citation (Scopus)

Abstract

We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].

Original language	English
Number of pages	2
Journal	Alimentary Pharmacology & Therapeutics
DOIs	https://doi.org/10.1111/apt.15814
Publication status	Accepted/In press - 6 May 2020

Access to Document

10.1111/apt.15814

310937691-in press-oaAccepted author manuscript, 315 KB

Link to publication in Scopus

Cite this

Garg, M., Royce, S. G., & Lubel, J. S. (Accepted/In press). Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.15814

@article{2f110f52e6d7494cb64c9fde19e2e024,

title = "Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors",

abstract = "We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].",

author = "Mayur Garg and Royce, {Simon G.} and Lubel, {John S.}",

year = "2020",

month = may

day = "6",

doi = "10.1111/apt.15814",

language = "English",

journal = "Alimentary Pharmacology & Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Letter

T2 - intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors

AU - Garg, Mayur

AU - Royce, Simon G.

AU - Lubel, John S.

PY - 2020/5/6

Y1 - 2020/5/6

N2 - We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].

AB - We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].

UR - http://www.scopus.com/inward/record.url?scp=85084616470&partnerID=8YFLogxK

U2 - 10.1111/apt.15814

DO - 10.1111/apt.15814

M3 - Letter

C2 - 32374032

AN - SCOPUS:85084616470

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

SN - 0269-2813

ER -